| Literature DB >> 30408070 |
LaMont Cannon1,2, Cesar A Vargas-Garcia3,4, Aditya Jagarapu1, Michael J Piovoso3, Ryan Zurakowski1,3.
Abstract
Clinical trials are necessary in order to develop treatments for diseases; however, they can often be costly, time consuming, and demanding to the patients. This paper summarizes several common methods used for optimal design that can be used to address these issues. In addition, we introduce a novel method for optimizing experiment designs applied to HIV 2-LTR clinical trials. Our method employs Bayesian techniques to optimize the experiment outcome by maximizing the Expected Kullback-Leibler Divergence (EKLD) between the a priori knowledge of system parameters before the experiment and the a posteriori knowledge of the system parameters after the experiment. We show that our method is robust and performs equally well if not better than traditional optimal experiment design techniques.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30408070 PMCID: PMC6224063 DOI: 10.1371/journal.pone.0206700
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Model parameter definitions.
| Parameter | Definition | Units |
|---|---|---|
| concentration of infected cells | cells/106PBMC | |
| concentration of 2-LTR circles | 2LTR/106PBMC | |
| R | probability infected cell infects a target cell in a generation | unitless |
| a | death rate of actively infected cells | |
| rate of exogenous production of infected | infected cells/ 106PBMC×Day | |
| Ratio-reduction in R following integrase inhibitor intensification | unitless | |
| binary variable: 1 when integrase inhibitor is applied and 0 when it is not | unitless | |
| Ratio of probability of 2-LTR formation with integrase inhibitor vs. without | unitless | |
| k | The probability of 2-LTR circle formation when integrase inhibitor is present | 2LTR/ infected cells |
| decay rate of 2-LTR circles | day−1 |
Fig 1Sigma point patient dynamics.
Fig 26 point sample schedules.
Fig 36 point schedule analysis.
Six-point sample schedules.
| Samples | EKLD | ||||||
|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | ||
| A-optimal | 0 | 1 | 4 | 9 | 27 | 28 | 3.51 |
| D-optimal | 0 | 1 | 2 | 4 | 11 | 26 | 3.80 |
| T-optimal | 1 | 2 | 3 | 4 | 5 | 6 | 3.28 |
| E-optimal | 0 | 2 | 4 | 10 | 26 | 27 | 3.52 |
| EKLD | 1 | 2 | 3 | 11 | 27 | 46 | 3.83 |
| Buzon | 0 | 14 | 28 | 84 | 168 | 336 | 2.48 |
Fig 44 point sample schedules.
Fig 54 point schedule analysis.
Four-point sample schedules.
| Samples | EKLD | ||||
|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | ||
| A-optimal | 1 | 4 | 5 | 12 | 3.04 |
| D-optimal | 0 | 2 | 6 | 12 | 2.82 |
| T-optimal | 2 | 3 | 4 | 5 | 2.69 |
| E-optimal | 0 | 3 | 5 | 46 | 2.90 |
| EKLD | 1 | 2 | 15 | 16 | 3.16 |
| Hatano | 0 | 7 | 14 | 56 | 2.43 |
Fig 6qPCR vs. ddPCR measurement error.
Fig 76 point ddPCR schedule analysis.
Six-point sample schedules EKLD.
| Schedules | ||||||
|---|---|---|---|---|---|---|
| EKLD | D | T | A | E | Buzon | |
| qPCR | 3.83 | 3.80 | 3.28 | 3.51 | 3.52 | 2.48 |
| ddPCR | 6.62 | 6.50 | 6.46 | 6.24 | 6.24 | 3.46 |
Fig 84 point ddPCR schedule analysis.
Four-point sample schedules EKLD.
| Schedules | ||||||
|---|---|---|---|---|---|---|
| EKLD | D | T | A | E | Hatano | |
| qPCR | 3.16 | 2.82 | 2.69 | 3.04 | 2.90 | 2.43 |
| ddPCR | 6.02 | 5.37 | 5.50 | 5.83 | 5.10 | 3.68 |